Form 4: Revolution Medicines Director Sushil Patel Executes Stock Option and Sells Shares Under 10b5-1 Plan

Director Sushil Patel of Revolution Medicines exercised stock options and sold shares on October 31, 2024, under a pre-arranged 10b5-1 trading plan.

Summary

• On October 31, 2024, Sushil Patel, a director of Revolution Medicines, exercised stock options to acquire 5,000 shares of common stock at a price of $24.84 per share.
• Simultaneously, Patel sold 5,000 shares of Revolution Medicines' common stock at a weighted average price of $54.1429, with individual sales prices ranging from $54.00 to $54.30.
• These transactions were executed under a pre-existing 10b5-1 trading plan adopted on September 7, 2023.
• Following these transactions, Patel directly owns 19,948 shares of common stock and 13,400 stock options.
• The reported direct ownership includes 7,748 restricted stock units.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the filing simply reports transactions executed under a pre-existing trading plan. There's no indication of positive or negative sentiment towards the company's prospects.

Industry Context

Form 4 filings are standard disclosures required by the SEC when company insiders, like directors and officers, trade their company's stock. These filings are closely watched by investors for insights into management's perspective on the company's value and future prospects. The use of a 10b5-1 trading plan suggests that these trades were pre-planned and not based on any specific non-public information at the time of the transaction.

Key Dates